anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Prodn. of antihaemophilia factor (AHF) concentrate comprises (1) purifying an aq. soln of AHF proteins; (2) ultrafiltration of the purified soln. to remove water, then (3) mixing the concentrate with buffer and saline. The resulting soln. is then opt. freeze-dried. - Pref. purification is by mixing with aluminium hydroxide adsorbent and ultrafiltration is through a membrane having a nominal mol wt. cut-off 10000-300000; particularly a hollow-fibre membrane. After ultrafiltration, the soln. can be purified further by adding glycine (before mixing with buffer and saline). Ultrafiltration is carried out without loss of AHF activity (contrast conventional reprecipitation-ultrafiltration) and the prod. has a significantly higher content of von Willebrandt factor which also has a longer invivo half-life. The ratio of AHF:fibrinogen is improved, about 3:1, so the danger of fibrinogen overload is avoided. EPAB- EP-126789 B A process for the production of antihemophilic factor concentrate, characterised in that it comprises the steps of (a) subjecting an aqueous solution of an antihemophilic blood plasma cryoprecipitate to purification by mixing with an aluminium hydroxide absorbent, (b) subjecting the aqueous solution to ultrafiltration using an ultrafiltration membrane having a nominal molecular weight cut-off within the range of 10,000 to 300,000 daltons, (c) mixing the ultrafiltered aqueous solution with glycine, (d) dissolving the paste obtained in step (c) and mixing the solution with buffer and saline, and (e) obtionally freeze-drying the ultrafiltered aqueous solution of step (d). (10pp) - EP-126789 B A process for the production of antihemophilic factor concentrate, characterised in that it comprises the steps of (a) subjecting an aqueous solution of an antihemophilic blood plasma cryoprecipitate to purification by mixing with an aluminium hydroxide absorbent, (b) subjecting the aqueous solution to ultrafiltration using an ultrafiltration membrane having a nominal molecular weight cut-off within the range of 10,000 to 300,000 daltons, (c) mixing the ultrafiltered aqueous solution with glycine, (d) dissolving the paste obtained in step (c) and mixing the solution with buffer and saline, and (e) optionally freeze-drying the ultrafiltered aqueous solution of step (d).
By transducing cells with an HIV-1-MN molecular clone deleted in the major packaging sequence, a stable HIV-1 packaging cell line, 422 was produced. 422 cells form syncytia with CD4 positive cells, correctly express HIV-1 structural proteins, and produce large amounts of mature particles with normal RT activity. These particles are not infectious. When stably transfected with an HIV-based retroviral vector, the 422 cell line produces hybrid virions capable of transducing CD4 positive cells with high efficiency (e.g., 105 cells/ml). The availability of this stable, noninfectious HIV-1 packaging cell line capable of generating high titer HIV vectors enables the use of HIV-1 based nucleic acids delivery systems, for example, in gene therapy. An HIV-2 based vector is packaged by the packaging cell lines, demonstrating that HIV-2 cell transformation vectors are packaged by the packaging cell line. HIV based vectors packaged by the high efficiency cell lines are shown to have anti-HIV activity per se.
The cuff pressure of the tracheal tube will be monitored continuously using a pneumatic device in the automatic group. The target endotracheal tube cuff pressure will be 20 cm H2O during the follow-up of patients.
The potential carcinogenicity of azacitidine was evaluated in mice and rats. Azacitidine induced tumors of the hematopoietic system in female mice at 2.2 mg/kg (6.6 mg/m², approximately 8% the recommended human daily dose on a mg/m² basis) administered IP three times per week for 52 weeks. An increased incidence of tumors in the lymphoreticular system, lung, mammary gland, and skin was seen in mice treated with azacitidine IP at 2.0 mg/kg (6.0 mg/m², approximately 8% the recommended human daily dose on a mg/m² basis) once a week for 50 weeks. A tumorigenicity study in rats dosed twice weekly at 15 or 60 mg/m² (approximately 20%-80% the recommended human daily dose on a mg/m² basis) revealed an increased incidence of testicular tumors compared with controls. 

The mutagenic and clastogenic potential of azacitidine was tested in in vitro bacterial systems Salmonella typhimurium strains TA100 and several strains of trpE8, Escherichia coli strains WP14 Pro, WP3103P, WP3104P, and CC103; in in vitro forward gene mutation assay in mouse lymphoma cells and human lymphoblast cells; and in an in vitro micronucleus assay in mouse L5178Y lymphoma cells and Syrian hamster embryo cells. Azacitidine was mutagenic in bacterial and mammalian cell systems. The clastogenic effect of azacitidine was shown by the induction of micronuclei in L5178Y mouse cells and Syrian hamster embryo cells. 

Administration of azacitidine to male mice at 9.9 mg/m² (approximately 9% the recommended human daily dose on a mg/m² basis) daily for 3 days prior to mating with untreated female mice resulted in decreased fertility and loss of offspring during subsequent embryonic and postnatal development. Treatment of male rats 3 times per week for 11 or 16 weeks at doses of 15-30 mg/m² (approximately 20%-40%, the recommended human daily dose on a mg/m² basis) resulted in decreased weight of the testes and epididymides, and decreased sperm counts accompanied by decreased pregnancy rates and increased loss of embryos in mated females. In a related study, male rats treated for 16 weeks at 24 mg/m² resulted in an increase in abnormal embryos in mated females when examined on day 2 of gestation.
Pregnant women have difficulty choosing among the wide variety of prenatal screening options available. To help pregnant women and their partners make informed decisions based on their values, needs and preferences, a decision aid (DA) has been developped and online shared decision-making (SDM) training program for health professionals has been created to support the use of this DA and give health care professionals key elements on SDM. The decision aid was found relevant and acceptable to pregnant women and their partners; the relevance and acceptability of the online SDM training program aren't evaluated yet. This study aim to assess the intention on using a DA after taking the online training program, to evaluate knowledge acquisition and to assess the program's acceptability and perceived usefulness. This is a multi-center, two-arm, controlled trial (RCT). Thirty-six participants will be randomly allocated to either 1) an experimental group that is exposed to the investigator's complete 3 hours online training program intervention (n = 18) or 2) a control group that is exposed to an intervention which will be a 3 hours online training program focused on prenatal screening alone.
SELZENTRY antagonizes the CCR5 co-receptor located on some immune cells, and therefore could potentially increase the risk of developing infections. The overall incidence and severity of infection, as well as AIDS-defining category C infections, was comparable in the treatment groups during the Phase 3 treatment-experienced studies of SELZENTRY. While there was a higher rate of certain upper respiratory tract infections reported in the SELZENTRY arm compared to placebo (23% versus 13%), there was a lower rate of pneumonia (2% vs 5%) reported in subjects receiving SELZENTRY. A higher incidence of Herpes virus infections (11 per 100 patient-years) was also reported in the SELZENTRY arm when adjusted for exposure compared to placebo (8 per 100 patient-years). 

In the Phase 2b/3 study in treatment-naïve subjects, the incidence of AIDS-defining Category C events when adjusted for exposure was 1.8 for SELZENTRY compared to 2.4 for efavirenz per 100 patient-years of exposure.

Patients should be monitored closely for evidence of infections while receiving SELZENTRY.
The invention discloses a composite for medical use. The composite comprises a weight ratio of 20 to 20 : 7 to 4 : 1.5 to 0.5 among hydroxy safflower yellow A, salvianic acid a and ferulic acid. Through expriments, the inventor found that the effective components of conventional coronary heart disease medicine 'coronary heart disease medicine II' for preventing myocardial cells from dying are the three components (FTA), namely, the salvianic acid a, the hydroxy safflower yellow A and the ferulic acid, rather than the five components absorbed by the human body. The curative effect of great dose induction of the coronary heart disease medicine II is caused by the FTA absorbed into the human body. Therefore, the inventor adopts the three active components (FTA) to prepare the medicinal composite which treats the coronary heart disease and prevents the myocardial cells from dying. The dosage of the medicine is small, the curative effect is more stable, and the production cost is low.
The present disclosure relates to a heterocyclic compound containing a purine ring system. The present disclosure relates to the use of ganciclovir (GCV) in the preparation of a drug for treating allergic rhinitis (AR), wherein the use method comprises using ganciclovir as the only active component or using ganciclovir in combination with other drugs that alleviate allergic rhinitis. Provided in the present disclosure is the use of ganciclovir in the preparation of a drug for treating allergic rhinitis. Studies show that ganciclovir can effectively alleviate symptoms and improve the life quality of an AR patient who does not respond to treatment with an anti-allergy drug in clinical practice. Transcriptomics also reveals that GCV regulates the functions of nasal mucosal ciliated cells, goblet cells and leukocytes. An in-vitro PBMCs drug test shows that GCV can change the immune balance in the body by means of increasing regulatory T cells, so as to alleviate allergy symptoms.
An initial dose of cetuximab (400 mg/m2 i.v. over 120 minutes) will be administered 1 week prior to the initiation of chemotherapy. Thereafter, cetuximab will be infused weekly at maintenance doses of 250 mg/m2 (over 60 minutes). On the first day of each cycle (every 3 weeks) of therapy, a 3-hour paclitaxel (225 mg/m2) infusion will be administered 1-hour post completion of the cetuximab infusion, immediately followed by a 30-minute carboplatin (AUC=6) infusion.
Pain is one of the most common and significant postoperative events experienced by many surgical patients. Orthopedic surgery is a relatively painful surgery due to the significant amount of bone and soft tissue resection, damage, and reconstruction. After thigh surgery for sarcomas, the patient may experience any of three distinct types of pain, including acute postoperative pain, persistent long-term nociceptive pain, and neuropathic pain related to intraoperative nerve injuries. The management of pain in limb sparing surgery patients and amputated patients is crucial during the rehabilitation program and often its approach is multidisciplinary. The ultrasound-guided supra-inguinal fascia iliaca block further built on earlier anatomic discoveries to more reliably anesthetize the three nerves: femoral, lateral femoral cutaneous, and obturator. The supra-inguinal fascia iliaca block has evolved as an effective means of providing analgesia to the thigh, the knee, and, most notably, the hip. Ultrasound-guided erector spinae plane block (ESPB) is an interfascial plane block reported in the treatment of postoperative pain from surgical procedures, ranging from shoulder to hip surgery. When performed at the lumbar 4th vertebral level, ESPB led to sensorial blockage between Th12 and L4 dermatomes lead to effective postoperative analgesia in hip and proximal femoral surgery. Although supra-inguinal fascia iliaca block and L-ESPB successfully reduced postoperative opioid consumption in previous study, no study has ever compared their efficacy in postoperative analgesia of adult patients undergoing oncologic thigh surgery under general anesthesia. Thus, in this randomized comparative study we are aiming to fill this gape in the literature.
Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype, and is associated with the lowest cure rates in the limited-stage disease setting, as well as with the lowest overall survival in the metastatic setting. Preclinical studies indicate that cycles of fasting or calorie-restricted, low-carbohydrate, low-protein diets, also known as fasting-mimicking diets (FMDs), have synergistic cytotoxic effects when combined with chemotherapy agents, such as doxorubicin or cisplatin, in several in vitro and in vivo tumor models, including murine TNBC models. More recently, intermittent fasting has demonstrated highly synergistic antitumor effects when combined with metformin; of note, these effects are mediated through the concomitant inhibition of glycolysis (via fasting-induced hypoglycemia) and metformin-induced inhibition of mitochondrial oxidative phosphorylation (OXPHOS). Finally, small reports published so far indicate that cyclic fasting and FMDs are well tolerated in cancer patients, and can be safety combined with standard antitumor treatments.

Based on these data, the BREAKFAST trial was designed to investigate the antitumor activity of cyclic FMD, alone or in combination with metformin, in patients with localized TNBC. In this study, 90 patients with stage I-III TNBC will be randomized in a 1:1 ratio to receive approximately 6 months of standard preoperative anthracycline plus taxane chemotherapy in combination with eight triweekly cycles of 5-day FMD (Arm A), or the same chemotherapy-FMD regimen plus daily metformin (Arm B). The primary objective of the study is to demonstrate that one or both experimental treatments increase the rate of pCR from 45% (historical data) to 65%
Preparation and application of ABA type block copolymer with reversible gel sol characteristic, relating to the technical field of high polymer materials. The ABA type polymer has reversible sol-gel transition point temperature and temperature-sensitive phase transition characteristics which can be regulated and controlled in a wide temperature range, has good water solubility and can be completely dispersed in a short time. Wherein A is N, N-dimethylacrylamide, and B is homopolymer or copolymer of diacetone acrylamide or hydroxypropyl acrylate. ABA type triblock polymer is synthesized by a two-step method through RAFT polymerization. The aqueous solution of the ABA type triblock polymer is a thermosensitive hydrogel, and the redissolution of the polymer is good. The reversible sol-gel phase transition temperature of the aqueous dispersion of block copolymers can be controlled at-10 ℃ to 60 ℃ and is useful both at sub-zero and above-zero temperatures. The hydrogel can be used for carrying medicine, can be used as a coating of a polymer aqueous solution, and has the functions of fog prevention and ice prevention.
The invention relates to a deep nourishing skin care cream. The skin care cream is mainly used for body nourishing and maintenance. The ingredients of the skin care cream comprise deionized water, lavender essential oil, polydimethylsiloxane, allantoin, sodium hyaluronate, centella extractive, rose extractive, propylene glycol, corn protease, spermaceti wax stearyl alcohol and coconut oil. The skin care cream contains unique moisturizing and nourishing formula, and provides sufficient water and  nutrients for skin. The skin care cream is light and thin, can raise skin elasticity effectively. The skin care cream is antiaging, and keeps skin moist and white. In the preparation process, no poisonous or harmful materials are added. The skin care cream is mild, has no stimulation and is an ideal skin care product.
The investigators will recruit 200 nursing homes with approximately 24,560 residents from across the United States through collaborations with our stakeholders. Nursing homes will be randomized to one of two arms: 1) AHRQ-funded COVID-19 ECHO that includes 16 weekly telehealth sessions addressing COVID-19 guidelines and best practices or 2) AHRQ-funded COVID-19 ECHO plus an additional 9 sessions with a focus on CDC infection control training. Randomization will be stratified by characteristics of nursing homes to ensure balance among the two trial groups, including size (number of beds),geographic location, and current COVID-19 infection rate. Patient-centered outcomes (nursing home residents with COVID-19 infections, hospitalizations, deaths, and QOL) will be assessed at baseline, 4, 6, 12, and 18 months. Our study is guided by the RE-AIM framework to critically evaluate both effectiveness and implementation outcomes of the proposed intervention. The RE-AIM framework is frequently utilized to improve sustainable adoption and implementation of effective, generalizable, evidence-based interventions like Project ECHO.
Part B, C, D and E: LY3039478 administered orally three times per week (TIW) at a fixed dose determined in Part A for two 28 day cycles. Participants receiving benefit may continue until disease progression.
A medication container can include a frame, a drawer including slots, at least one of a first set of one or more sensors and a second set of one or more sensors, and an electronic transmitter. The slots in the drawer can receive cartridges containing medication. The first set of sensor(s) can detect whether the drawer has moved more than a preset distance into or out of the frame. The second set of sensor(s) can detect whether a cartridge has been removed from a corresponding slot and/or the contents of the cartridge. The electronic transmitter can transmit data characterizing at least one of whether the drawer has moved more than the preset distance into or out of the frame and whether the cartridge has been removed from the corresponding slot to a server computer via a communication network. Other medication containers and systems for generating alerts are described.
The invention provides a vaccine candidate strain SQ01delta meq with marek's disease virus meq gene editing deletion, construction and application. The SQ01 delta meq vaccine candidate strain of the invention has the preservation number of: CGMCC No.45864. The parent strain of the SQ01 delta meq vaccine candidate strain is MDV ultra-strong Chinese variant HNSQ01. After passaging the parental strain HNSQ in vitro, 925bp sized fragments were deleted on each of the two meq alleles of the viral genome using CRISPR/Cas9 gene editing techniques. Through PCR identification, gene clone sequencing, RT-qPCR analysis, IFA identification, SPF chicken virus attack experiments and the like, the SQ01Δmeq strain is ensured to completely lose pathogenicity and tumorigenicity of a host chicken, has no immunosuppression, and has good biological safety. Animal immune challenge protection evaluation experiments show that SQ01 delta meq has good immune protection, and the immune protection index to a parent strain reaches 80.0%. Therefore, the SQ01Δmeq strain constructed by the invention not only can be used as a candidate strain of the latest MD gene deletion vaccine, but also can be used for developing and utilizing a subsequent MD novel genetic engineering vaccine.
Illicit drug and alcohol abuse have significant negative consequences for individuals who inject drugs/use drugs (PWID/UDs), including decreased immune system function and increased viral pathogenesis. PWID/UDs are at high risk of contracting or transmitting viral illnesses such as human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV). In South Africa, a dangerous drug-taking method known as "Bluetoothing" has emerged among nyaope users, whereby the users of this drug, after injecting, withdraw blood from their veins and then reinject it into another user. Hence, the transmission of blood-borne viruses (BBVs) is exacerbated by this "Bluetooth" practice among nyaope users. Moreover, several substances of abuse promote HIV, HBV, and HCV replication. With a specific focus on the nyaope drug, viral replication, and transmission, we address the important influence of abused addictive substances and polysubstance use in this review.
A system and method for enabling interactive research and scheduling of medical procedures over a computer network. A server computer receives, from a client computer associated with a user, a request for medical procedure information relating to at least one medical procedure. In response to this request, the server computer retrieves, from at least one database, the corresponding medical procedure information. Once the information has been retrieved, the computer server displays the medical procedure information to the client computer. Next, the server computer receives, from said client computer, a request to schedule an appointment relating to the medical procedure. In response to this request, the server computer receives, from the client computer, appointment information relating to the desired appointment. Once the appointment has been received, the server computer displays an appointment confirmation to the client computer.
OBJECTIVE: In view of the increasing number of people with (multiple) chronic conditions, the Organisation for Economic Co-operation and Development (OECD) initiated the International Survey of People Living with Chronic Conditions (PaRIS survey), which aims to provide insight in patient-reported outcomes and experiences of chronic care provided by primary care practices to support policy development. The objective of this research note is to describe the structure of the data, collected in the PaRIS survey and how the data will be analysed in a multilevel approach for cross-country comparison.
ANALYSIS PLAN: The data structure of the PaRIS survey represents three levels: countries/health systems, primary care practices and patients. Multilevel analysis is used because of its accuracy in estimating country-level outcomes, its flexibility in modelling relationships, and its opportunities in connecting to relevant policy questions. Country-level outcomes will be estimated to facilitate cross-country comparison and (future) within-country comparison over time. Characteristics of patients that potentially explain variation in patient-reported outcomes and experiences can be linked to primary care practice and country/health system characteristics. This makes it possible to address policy-relevant questions relating, e.g., to the impact of chronic care management on patients with a specific chronic condition.